Septerna Inc/$SEPN
1D1W1MYTD1Y5YMAX
Capital at risk
About Septerna Inc
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
- Ticker
- $SEPN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 123
- Headquarters
- South San Francisco, United States
- Website
- septerna.com
Septerna Inc Metrics
BasicAdvanced
$1.8B
-
-$0.54
-
-
Price and volume
Market cap
$1.8B
52-week high
$51.10
52-week low
$14.35
Average daily volume
415K
Financial strength
Current ratio
4.995
Quick ratio
4.895
Long term debt to equity
0.052
Total debt to equity
0.058
Profitability
EBITDA (TTM)
-54.395
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-24.51%
Operating margin (TTM)
-56.68%
Effective tax rate (TTM)
-5.77%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
-7.13%
Return on equity (TTM)
-6.34%
Valuation
Price to revenue (TTM)
17.369
Price to book
4.54
Price to tangible book (TTM)
4.54
Price to free cash flow (TTM)
16.342
Free cash flow yield (TTM)
6.12%
Free cash flow per share (TTM)
2.352
Growth
Revenue change (TTM)
13,520.11%
Earnings per share change (TTM)
-80.92%
Bulls say / Bears say
Positive Phase 1 clinical data for SEP-631 demonstrated a tolerability profile comparable to placebo, supportive once-daily dosing pharmacokinetics, and robust pharmacodynamic suppression of icatibant-induced wheal formation, enabling a planned Phase 2b trial in chronic spontaneous urticaria in H2 2026 (Reuters)
Strong liquidity with $516.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations into at least 2029, underpinning sustained R&D investment (Thomson Reuters)
Collaboration revenue from Novo Nordisk surged to $26.7 million in Q2 2026 versus $0.1 million in Q2 2025, outpacing analyst estimates and providing material non-dilutive funding for pipeline advancement (Reuters)
R&D expenses surged 58% year-over-year to $35.1 million in Q2 2026 from $22.2 million in Q2 2025, reflecting a significant increase in cash burn to advance pipeline programs (NASDAQ)
General and administrative expenses rose to $8.5 million in Q2 2026 from $6.9 million in the year-ago quarter, indicating growing overhead costs amidst pre-commercialization operations (NASDAQ)
Key data readouts for lead programs remain distant—SEP-479 SAD/MAD results are not expected until Q1 2027 and SEP-631 Phase 2b initiation is contingent on long-term toxicology studies—prolonging clinical and regulatory uncertainty (NASDAQ)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Upcoming events
No upcoming events
Funds containing Septerna Inc
AllUSDGBPEUR
Fund name | Fund size | $SEPN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.12% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.12% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.